Total Funding: $174.6M
Headquarters: London, England, United Kingdom
Funding Status: M&A
Employee Number: 11-50
Estimated Revenue: $1M to $10M
Investment Stage: N/A
Last Funding Type: Post-IPO Equity
Number Of Exists: Post-IPO Equity
Technology: Neurological Disorders
Investor Type: Company
Investors Number: 4
Founded Date: 2013
Industry: Gene Therapy